当前临床指南对血液系统恶性肿瘤患者肺部侵袭性真菌感染的诊断局限与挑战及宏基因组测序的潜在应用
该综述检索近5年PubMed及专业学会网站,梳理血液系统恶性肿瘤(HM)患者肺部侵袭性真菌感染(pIFI)的指南诊断推荐及局限,并回顾宏基因组测序数据。现有指南推荐胸部CT及镜检、半乳甘露聚糖、β-D-葡聚糖、PCR和培养,但各有限制;真实世界数据支持宏基因组测序作为辅助手段,尚需高质量临床试验确定是否更新指南。
要点
- HM合并疑似pIFI的指南推荐胸部CT及镜检、半乳甘露聚糖、β-D-葡聚糖、PCR和培养,各有限制。
- 真实世界数据支持宏基因组测序作为pIFI及时诊断的辅助手段。
- 需高质量临床试验确定指南是否纳入新型诊断技术。
核心结论
- 当前指南对HM患者pIFI的诊断推荐存在局限且缺乏共识,可能导致诊断方法不一致;宏基因组测序的真实世界数据支持其作为辅助诊断,但需高质量临床试验确定指南是否更新。
研究设计与样本
- 综述:检索PubMed、专业联盟和科学学会网站,纳入近5年已发表的循证临床指南,并检索PubMed中描述临床相关新型诊断技术的论文。
主要发现
- 当前HM疑似pIFI指南推荐胸部CT及镜检(包括荧光增白剂染色、组织病理学、细胞病理学等)、曲霉半乳甘露聚糖、β-D-葡聚糖、PCR和培养,各有限制。
- 新兴真实世界数据支持基于宏基因组测序的检测用于pIFI的及时诊断。
关键数值与推荐
- 指南推荐对HM疑似pIFI患者行胸部CT及镜检、曲霉半乳甘露聚糖、β-D-葡聚糖、PCR和培养。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需高质量稳健临床试验确定指南是否应更新以纳入新型诊断技术。
- 试验应探讨强效新型诊断技术(如病原体不可知宏基因组测序)联合传统检测能否优化所有潜在pIFI病原体的诊断产出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary invasive fungal infections (pIFI) disproportionately affect patients with haematological malignancies (HM). Establishing a rapid and accurate diagnosis of pIFI is challenging. Multiple guidelines recommend diagnostic testing of invasive fungal infections but lack consensus and may contribute to inconsistent diagnostic approaches. OBJECTIVE: To identify key diagnostic challenges and review metagenomic sequencing data. SOURCES: PubMed, professional consortium, and scientific society websites search to identify relevant, published, evidence-based clinical guidelines within the past 5 years. PubMed searchs for papers describing clinically relevant novel diagnostic technologies. CONTENT: Current guidelines for patients with HM and suspected pIFI recommend chest computed tomography imaging and specimen testing with microscopic examination (including calcofluor white stain, histopathology, cytopathology, etc.), Aspergillus galactomannan, β-D-glucan, PCR, and culture, each with certain limitations. Emerging real-world data support the adjunctive use of metagenomic sequencing-based tests for the timely diagnosis of pIFI. IMPLICATIONS: High-quality evidence from robust clinical trials is needed to determine whether guidelines should be updated to include novel diagnostic technologies. Trials should ask whether the combination of powerful novel diagnostics, such as pathogen-agnostic metagenomic sequencing technologies in conjunction with conventional testing can optimize the diagnostic yield for all potential pIFI pathogens that impact the health of patients with HM.
引用
- Park SY, Ardura MI, Zhang SX, et al. Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematological malignancies. Clin Microbiol Infect. 2024. PMID: 38460819. doi:10.1016/j.cmi.2024.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。